Jee Eun Yang; Seung R. Paik

doi:10.7599/hmr.2013.33.2.123

Journal List > Hanyang Med Rev > v.33(2) > 1044146

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yang and Paik: Amyloidogenic Protein of α-Synuclein

Review Article

Hanyang Medical Reviews 2013; 33(2): 123-129.

Published online: 23 May 2013

DOI: https://doi.org/10.7599/hmr.2013.33.2.123

Amyloidogenic Protein of α-Synuclein

Jee Eun Yang, Seung R. Paik

School of Chemical and Biological Engineering, Seoul National University, Seoul, Korea.

Correspondence to: Seung R. Paik. School of Chemical and Biological Engineering, Seoul National University, 302-911, 1 Gwanak-ro, Gwanak-gu, Seoul 151-744, Korea. Tel: +82-2-880-7414, Fax: +82-2-888-7295, srpaik@snu.ac.kr

Received 10 March 2013 Revised 29 April 2013 Accepted 3 May 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Amyloidogenesis is the key pathological phenomenon commonly observed in various neurodegenerative disorders. α-Synuclein is the major constituent of Lewy bodies as a common pathological signature of Lewy body diseases (LBDs) including Parkinson's disease (PD), PD with dementia (PDD), and Dementia with Lewy bodies (DLB). As proteins unfold, they would result in producing either ordered or disordered aggregates unless they are folded back to the native state by molecular chaperones or removed via proteolytic degradation. α-Synuclein known as a natively unfolded protein has self-assembled into the ordered protein aggregates of amyloid fibrils which comprise the radiating filaments found in Lewy bodies. Amyloid fibrils are generated via either a template-dependent or template-independent mechanism. The prevalent nucleation-dependent fibrillation accelerates the assembly process in the presence of seeds such as prefibrillar species. As a template-independent process, we have recently proposed the double-concerted fibrillation mechanism in which the oligomeric species of α-synuclein act as a growing unit to form the mature fibrils. Despite insufficient understanding of the toxic causes of α-synuclein, the oligomeric species have been suggested to be responsible for the cellular degeneration by influencing membrane stability while leaving the amyloid fibrils as a detoxification end product. Alternatively, the transition process from the oligomers to the fibrils has been proposed to affect cell viability. It is, therefore, expected to develop prophylactic and therapeutic strategies toward the synucleinopathies by studying cellular function of α-synuclein, molecular mechanism of its assembly into the amyloid fibrils, and their effects on cellular biogenesis. By studying cellular function of α-synuclein, its molecular mechanism of assembly into amyloid fibrils and their effects on cellular biogenesis, progress of prophylactic and therapeutic strategies toward synucleinopathy can be seen.

Keywords: Amyloidosis, Neurodegenerative Disorders, Parkinson Disease, alpha-Synuclein

Figures and Tables

Fig. 1

Intracellular folding of proteins and formation of protein aggregations (Ref. 3 with permission from Biochemistry and Molecular Biology News).

Fig. 2

Amyloid structure of PD-related α-synuclein (Ref. 3 with permission from Biochemistry and Molecular Biology News).

Fig. 3

Template-dependent fibrillation. (A) Fibrillar growth with active monomers. The monomers convert to the amyloidogenic conformer upon binding to the template. (B) Amyloid fibril growth with passive monomers. The amyloidogenic conformers are selected by the template from the pre-existing conformational equilibrium and amyloid fibrils are elongated. (Ref. 14 with permission from BMB Reports).

Fig. 4

Template-independent fibrillations. (A) Ligand-induced fibrillation, (B) Fibrillar polymorphisms induced by multiple ligand interactions (Ref. 14 with permission from BMB Reports).

Fig. 5

Models of amyloidogenesis. (A) Nucleationdependent fibrillation, (B) Double- concerted fibrillation (Ref. 14 with permission from BMB Reports).

Fig. 6

Primary structure of α-Synuclein and its interactive ligands. NAC, non-amyloid component.

References

1. Sipe JD. Amyloidosis. Annu Rev Biochem. 1992; 61:947–975.

2. Virchow R. Zur cellulose-frage. Virchows Archiv. 1855; 8:140–144.

3. Paik SR, Lee JH. Strategy to control the protein aggregation: neurodegenerative disorders and amyloid. Biochem Mol Biol News. 2007; 27:23–29.

4. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000; 247:Suppl 2. II3–II10.

5. Shults CW. Lewy bodies. Proc Natl Acad Sci U S A. 2006; 103:1661–1668.

6. Sunde M, Blake CC. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys. 1998; 31:1–39.

7. Knowles TP, Fitzpatrick AW, Meehan S, Mott HR, Vendruscolo M, Dobson CM, et al. Role of intermolecular forces in defining material properties of protein nanofibrils. Science. 2007; 318:1900–1903.

8. Tan SY, Pepys MB. Amyloidosis. Histopathology. 1994; 25:403–414.

9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349:583–596.

10. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002; 418:291.

11. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003; 26:267–298.

12. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem. 2000; 275:19439–19442.

13. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem. 2002; 277:40302–40308.

14. Bhak G, Choe YJ, Paik SR. Mechanism of amyloidogenesis: nucleation-dependent fibrillation versus double-concerted fibrillation. BMB Rep. 2009; 42:541–551.

15. Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999; 309:305–318.

16. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993; 73:1055–1058.

17. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997; 66:385–407.

18. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem. 1999; 274:19509–19512.

19. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276:2045–2047.

20. Ulmer TS, Bax A, Cole NB, Nussbaum RL. Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem. 2005; 280:9595–9603.

21. Eliezer D, Kutluay E, Bussell R Jr, Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol. 2001; 307:1061–1073.

22. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J. 2004; 18:617–626.

23. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2001; 276:2380–2386.

24. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995; 14:467–475.

25. Withers GS, George JM, Banker GA, Clayton DF. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res. 1997; 99:87–94.

26. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994; 345:27–32.

27. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002; 22:8797–8807.

28. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000; 25:239–252.

29. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010; 30:8083–8095.

30. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010; 65:66–79.

31. Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A. 2012; 109:3213–3219.

32. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010; 329:1663–1667.

33. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011; 10:1015–1025.

34. Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, et al. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet. 2003; 12:2625–2635.

35. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305:1292–1295.

36. Kragh CL, Ubhi K, Wyss-Coray T, Masliah E. Autophagy in dementias. Brain Pathol. 2012; 22:99–109.

37. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998; 4:1318–1320.

38. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990; 237:197–204.

39. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci. 2012; 32:3301–3305.

40. Horvath I, Weise CF, Andersson EK, Chorell E, Sellstedt M, Bengtsson C, et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J Am Chem Soc. 2012; 134:3439–3444.

41. Iwatsubo T. Pathological biochemistry of alpha-synucleinopathy. Neuropathology. 2007; 27:474–478.

42. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 2000; 275:18344–18349.

43. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001; 276:44284–44296.

44. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001; 294:1346–1349.

45. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007; 27:9220–9232.

46. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013; 14:38–48.

TOOLS

Similar articles